Dislipidemia e terapia ipolipemizzante: Dalle linee guida alla pratica clinica Una rassegna aggiornata della letteratura

Translated title of the contribution: Dislipidemia and lipid lowering drugs: From guidelines to clinical practice. An updated review of the literature

Research output: Contribution to journalArticlepeer-review

Abstract

The atherosclerotic cardiovascular disease (ASCVD) represents the leading cause of death and disability not only in countries with a high degree of socio-economic development but also in low-middle-income countries. The study of atherosclerosis and the strategies to control ASCVD are evolving. All strategies emphasize the need to lower LDL cholesterol through an appropriate lifestyle and the use of lipid-lowering drugs. A therapy with statin with or without other lipid lowering drugs is recommended in secondary prevention. In primary prevention, the use of the lipid-lowering drug should instead take into account the cost-benefit ratio. Available evidence coming from clinical trials is useful to inform clinical choices but must be associated with a shared decision-making process between doctor and patient.

Translated title of the contributionDislipidemia and lipid lowering drugs: From guidelines to clinical practice. An updated review of the literature
Original languageItalian
Pages (from-to)426-443
Number of pages18
JournalRecenti Progressi in Medicina
Volume111
Issue number7
DOIs
Publication statusPublished - Aug 2020

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Dislipidemia and lipid lowering drugs: From guidelines to clinical practice. An updated review of the literature'. Together they form a unique fingerprint.

Cite this